دورية أكاديمية
Efficacy of tyrosine-kinase-2 and phosphodiesterase-4 inhibitors for scalp psoriasis: a systematic review and meta-analysis.
| العنوان: | Efficacy of tyrosine-kinase-2 and phosphodiesterase-4 inhibitors for scalp psoriasis: a systematic review and meta-analysis. |
|---|---|
| المؤلفون: | Tsiogkas SG; Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece., Karamitrou EK; Primary Health Center of Mouzaki, Karditsa, Greece., Grammatikopoulou MG; Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece., Zafiriou E; Department of Dermatology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece., Bogdanos DP; Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece. |
| المصدر: | Current medical research and opinion [Curr Med Res Opin] 2024 Feb; Vol. 40 (2), pp. 155-163. Date of Electronic Publication: 2024 Jan 24. |
| نوع المنشور: | Meta-Analysis; Systematic Review; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 0351014 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-4877 (Electronic) Linking ISSN: 03007995 NLM ISO Abbreviation: Curr Med Res Opin Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 1995- : Newbury, Berkshire, U.K. : Informa Healthcare Original Publication: London, M. D. Promotions, ltd. |
| مواضيع طبية MeSH: | Phosphodiesterase 4 Inhibitors*/therapeutic use , Psoriasis*/drug therapy, Thalidomide/*analogs & derivatives, Humans ; Cyclic Nucleotide Phosphodiesterases, Type 4/therapeutic use ; TYK2 Kinase/therapeutic use ; Scalp ; Tyrosine/therapeutic use ; Severity of Illness Index ; Treatment Outcome ; Randomized Controlled Trials as Topic |
| مستخلص: | Objectives: Psoriasis of the scalp is challenging to manage. The only approved oral tyrosine kinase 2 and phosphodiesterase 4 inhibitors for psoriasis are deucravacitinib and apremilast. The aim of this study was to explore their efficacy for scalp psoriasis utilizing data from randomized controlled trials. Methods: We searched Medline, Scopus, Web of Science, CENTRAL, and ClinicalTrials.gov up to August 4, 2023. To determine risk of bias, the revised Risk of Bias assessment tool 2.0 was used. Inverse variance random effects meta-analyses were executed. Heterogeneity was assessed utilizing Q and I 2 statistics. Pre-determined outcomes included the proportion of participants with cleared scalp skin (Scalp Physician's Global Assessment [ScPGA] of 0/1), mean change in Psoriasis Scalp Severity Index (PSSI), and mean improvement in Dermatology Life Quality Index (DLQI). Results: Ten RCTs fulfilled inclusion criteria. Both apremilast (RR = 2.41, 95% CI = 2.08-2.79, Tau 2 = 0, I 2 = 0) and deucravacitinib (RR = 3.86, 95% CI = 3.02-4.94, Tau 2 = 0, I 2 = 0) were more effective in inducing ScPGA of 0/1 at 16 weeks compared to placebo. Furthermore, deucravacitinib was more effective than apremilast (RR = 1.70, 95% CI = 1.44-2.00, Tau 2 = 0, I 2 = 0). An analysis could not be executed for the rest of the outcomes. Conclusions: Apremilast and deucravacitinib are effective for scalp psoriasis. Deucravacitinib may be more efficient in clearing the scalp. |
| فهرسة مساهمة: | Keywords: BMS-986165; localized psoriasis; otezla; scalp psoriasis |
| المشرفين على المادة: | UP7QBP99PN (apremilast) 0 (Phosphodiesterase 4 Inhibitors) EC 3.1.4.17 (Cyclic Nucleotide Phosphodiesterases, Type 4) EC 2.7.10.2 (TYK2 Kinase) 42HK56048U (Tyrosine) 4Z8R6ORS6L (Thalidomide) |
| تواريخ الأحداث: | Date Created: 20231124 Date Completed: 20240125 Latest Revision: 20240419 |
| رمز التحديث: | 20240420 |
| DOI: | 10.1080/03007995.2023.2288280 |
| PMID: | 37997745 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1473-4877 |
|---|---|
| DOI: | 10.1080/03007995.2023.2288280 |